Startseite>>Signaling Pathways>> Microbiology & Virology>> Parasite>>Tafenoquine Succinate (WR 238605 (Succinate))

Tafenoquine Succinate (WR 238605 (Succinate))

Katalog-Nr.GC32206

Tafenoquine Succinate (WR 238605 (Succinate)) (WR 238605 Succinate) ist ein 8-Aminochinolin.

Products are for research use only. Not for human use. We do not sell to patients.

Tafenoquine Succinate (WR 238605 (Succinate)) Chemische Struktur

Cas No.: 106635-81-8

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
282,00 $
Auf Lager
5mg
220,00 $
Auf Lager
10mg
331,00 $
Auf Lager
50mg
1.011,00 $
Auf Lager
100mg
1.471,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com


Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Tafenoquine Succinate (WR 238605 Succinate) is an 8-aminoquinoline. Tafenoquine is an anti-malarial prophylactic agent[1].

Tafenoquine exhibits no anti-malarial activity in CYP 2D knock-out mice when dosed at their ED100 values (3 mg/kg) established in WT mice. Tafenoquine anti-malarial activity is partially restored in humanized/CYP 2D6 knock-in mice when tested at two times its ED100 (6 mg/kg)[1].

[1]. Marcsisin SR, et al. Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds. Malar J. 2014 Jan 3;13:2.

Bewertungen

Review for Tafenoquine Succinate (WR 238605 (Succinate))

Average Rating: 5 ★★★★★ (Based on Reviews and 28 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Tafenoquine Succinate (WR 238605 (Succinate))

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.